AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
Go back to AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder| ATA, Inc. (NASDAQ: ATAI) | Delayed: 7.21 -0.04 (0.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.25 | 52 Week High | $7.32 | |||
| Open | $7.24 | 52 Week Low | $3.30 | |||
| Day High | $7.26 | P/E | N/A | |||
| Day Low | $7.21 | EPS | $0.00 | |||
| Volume | 3,662,691 | |||||
